Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management

American Journal of Hematology

Volumn 88, Issue 6, 2013, Pages 507-516

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BUSULFAN; HYDROXYUREA; JANUS KINASE 2;

AGE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING TENDENCY; CARDIOVASCULAR RISK; CHRONIC MYELOID LEUKEMIA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LEUKOCYTOSIS; LOW DRUG DOSE; LOW RISK POPULATION; MEDICAL HISTORY; MYELOFIBROSIS; PHLEBOTOMY; POLYCYTHEMIA VERA; PREFIBROTIC MYELOFIBROSIS; PRIORITY JOURNAL; REACTIVE THROMBOCYTOSIS; REFRACTORY ANEMIA WITH RING SIDEROBLASTS ASSOCIATED WITH MARKED THROMBOCYTOSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RISK ASSESSMENT; SURVIVAL TIME; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; VON WILLEBRAND DISEASE; BLOOD; RISK FACTOR; SURVIVAL;

HUMANS; POLYCYTHEMIA VERA; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOCYTOSIS;

EID: 84878169183     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23417     Document Type: Article

References (119)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
3. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-1138.
4. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-1963.
5. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia 2008;22:1299-1307.
6. Scott LM. The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol 2011;86:668-676.
7. Pardanani A, Lasho TL, Finke CM, Tefferi A. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol 2011;86:701-702.
8. Boyd EM, Bench AJ, Goday-Fernandez A, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 149:250-257.
9. Ohashi H, Arita K, Fukami S, et al. Two rare MPL gene mutations in patients with essential thrombocythemia. Int J Hematol 2009;90:431-432.
10. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood 2008;112:141-149.
11. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103:4198-4200.
12. Liu K, Martini M, Rocca B, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica 2009;94:1368-1374.
13. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. New Engl J Med 2012;366:967-969.
14. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24:1302-1309.
15. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.
16. Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012;51:743-755.
17. Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011;25:1217-1219.
18. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-1579.
19. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol 2011;29:3179-3184.
20. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients. Blood 2011;117:5857-5859.
21. Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011;117:2813-2816.
22. Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: Comparison of survival and clinical features involving 603 patients. Leukemia 2011;25:1834-1839.
23. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112:844-847.
24. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007;137:244-247.
25. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097.
26. Tefferi A, Sirhan S, Lasho TL, et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol. 2005;131:166-171.
27. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006;20:350-353.
28. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004;89:1194-1198.
29. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br J Haematol 2005;131:208-213.
30. Thiele J, Kvasnicka HM, Vardiman JW, et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol 2009;27:e220-221; author reply e222-223.
31. Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008;93:34-40.
32. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. Am J Hematol 2010;85:62-69.
33. Michiels JJ, Berneman Z, Schroyens W, et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: Natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol 2004;83:504-512.
34. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-438.
35. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132.
36. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979;43:185-190.
37. Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 2008;22:1494-1502.
38. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128-5133; quiz 5252.
39. Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984;64:981-985.
40. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007;138:354-358.
41. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761.
42. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients. Leukemia 2007;21:270-276.
43. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: A study of 605 patients. Haematologica 2008;93:1645-1651.
44. Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: A population-based study of 327 patients. Br J Haematol 2013;160:251-254.
45. Tefferi A. Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. Am J Hematol 2009;85:93-94.
46. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: Is leukocytosis a causative factor? Blood 2009;114:759-763.
47. Tefferi A, Passamonti F. Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. Am J Hematol 2009;84:629-630.
48. Passamonti F, Rumi E, Randi ML, Morra E, Cazzola M. Aspirin in pregnant patients with essential thrombocythemia: A retrospective analysis of 129 pregnancies. J Thromb Haemost 2010;8:411-413.
49. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: A single institution study of 63 pregnancies. Eur J Haematol 2009;82:350-353.
50. Crisa E, Venturino E, Passera R, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol 2010;89:691-699.
51. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007;33:313-320.
52. Diehn F, Tefferi A. Pruritus in polycythaemia vera: Prevalence, laboratory correlates and management. Br J Haematol 2001;115:619-621.
53. Michiels JJ, Berneman Z, Schroyens W, et al. The paradox of platelet activation and impaired function: Platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006;32:589-604.
54. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.
55. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010;116:1205-1210; quiz 1387.
56. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. New Engl J Med 2013;368:22-33.
57. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand. 1962;172:513-523.
58. Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006;17:528-544.
59. Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Int Med 1985;102:466-471.
60. van Genderen PJ, Lucas IS, van Strik R, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost 1996;76:333-338.
61. van Genderen PJ, Michiels JJ, van Strik R, et al. Platelet consumption in thrombocythemia complicated by erythromelalgia: Reversal by aspirin. Thromb Haemost 1995;73:210-214.
62. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595-3603.
63. Niittyvuopio R, Juvonen E, Kaaja R, et al. Pregnancy in essential thrombocythaemia: Experience with 40 pregnancies. Eur J Haematol 2004;73:431-436.
64. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001;66:152-159.
65. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 2007;110:485-489.
66. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: The need for an observational study in Europe. Semin Thromb Hemost 2006;32:422-429.
67. Elliott MA, Tefferi A. Thrombocythaemia and pregnancy. Best Pract Res Clin Haematol 2003;16:227-242.
68. Vaa BE, Wolanskyj AP, Roeker L, et al. Pruritus in primary myelofibrosis: Clinical and laboratory correlates. Am J Hematol, in press.
69. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002;99:2627.
70. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: Critical assessment of value and limitations. Leukemia 2011;25:218-225.
71. Muller EW, de Wolf JT, Egger R, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br J Haematol 1995;89:313-318.
72. Baldo A, Sammarco E, Plaitano R, et al. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol 2002;147:979-981.
73. Kayacioglu I, Gunay R, Saskin H, et al. The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. Heart Surg Forum 2008;11:E152-E157.
74. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
75. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-796.
76. Budde U, Dent JA, Berkowitz SD, et al. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986;68:1213-1217.
77. Lopez-Fernandez MF, Lopez-Berges C, Martin R, et al. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. Thromb Haemost 1987;58:753-757.
78. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-4244.
79. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488-494.
80. Michiels JJ, Budde U, van der Planken M, et al. Acquired von Willebrand syndromes: Clinical features, aetiology, pathophysiology, classification and management. Best Pract Clin Haematol 2001;14:401-436.
81. van Genderen PJ, Budde U, Michiels JJ, et al. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996;93:962-965.
82. van Genderen PJ, Prins FJ, Lucas IS, et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: Normalization after cytoreduction of the increased platelet count. Br J Haematol 1997;99:832-836.
83. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): Detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000;83:127-135.
84. Wehmeier A, Fricke S, Scharf RE, Schneider W. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol 1990;45:191-197.
85. Wehmeier A, Scharf RE, Fricke S, Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: Relation of platelet disorders to clinical aspects of the disease. Haemostasis 1989;19:251-259.
86. Gersuk GM, Carmel R, Pattengale PK. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood 1989;74:2330-2334.
87. Burstein SA, Malpass TW, Yee E, et al. Platelet factor-4 excretion in myeloproliferative disease: Implications for the aetiology of myelofibrosis. Br J Haematol 1984;57:383-392.
88. Wehmeier A, Tschope D, Esser J, et al. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991;61:271-278.
89. Kaywin P, McDonough M, Insel PA, Shattil SJ. Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. New Engl J Med 1978;299:505-509.
90. Mazzucato M, De Marco L, De Angelis V, et al. Platelet membrane abnormalities in myeloproliferative disorders: Decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol 1989;73:369-374.
91. Le Blanc K, Lindahl T, Rosendahl K, Samuelsson J. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. Thromb Res 1998;91:287-295.
92. Jensen MK, de Nully Brown P, Lund BV, et al. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders.[see comment]. Br J Haematol 2000;110:116-124.
93. Tefferi A, Smock KJ, Divgi AB. Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count. Am J Hematol 2010;85:545.
94. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304:441-447.
95. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: A summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI, editors. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: W.B. Saunders; 1995. pp 166-194.
96. Treatment of polycythaemia vera by radiophosphorus or busulphan: A randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 1981;44:75-80.
97. Najean Y, Rain JD. Treatment of polycythemia vera-The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370-3377.
98. Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29:3907-3913.
99. Najean Y, Rain JD. Treatment of polycythemia vera: Use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997;89:2319-2327.
100. Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986;23:172-176.
101. Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol (Paris) 2004;52:285-288.
102. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
103. Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared to hydroxyurea in WHO-classified essential thrombocythemia: The ANAHYDRET Study, a randomized controlled trial. Blood, in press.
104. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety-A polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17-23.
105. West WO. Hydroxyurea in the treatment of polycythemia vera: A prospective study of 100 patients over a 20-year period. South Med J 1987;80:323-327.
106. Tatarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin Hematol 1997;34:24-28.
107. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera. An analysis of 1, 638 patients enrolled in a prospective observational study. Blood 2005;105:2664-2670.
108. Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: Long-term results in 163 patients. Haematologica 2000;85:1011-1018.
109. Petti MC, Spadea A, Avvisati G, et al. Polycythemia vera treated with pipobroman as single agent: Low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). Leukemia 1998;12:869-874.
110. De Sanctis V, Mazzucconi MG, Spadea A, et al. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: Occurrence of leukaemic evolution. Br J Haematol 2003;123:517-521.
111. Passamonti F, Rumi E, Malabarba L, et al. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Ann Hematol 2004;83:495-497.
112. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: Retrospective study from one centre. Br J Haematol 1985;61:657-666.
113. D'Emilio A, Battista R, Dini E. Treatment of primary proliferative polycythaemia by venesection and busulphan. Br J Haematol 1987;65:121-122.
114. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 1998;91:616-622.
115. Shvidel L, Sigler E, Haran M, et al. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia 2007;21:2071-2072.
116. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008;22:1990-1998.
117. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418-5424.
118. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-3072.
119. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood 2010;115:2354-2363.